Pfizer (NYSE:PFE) Trading Up 1.2% on Analyst Upgrade

Pfizer Inc. (NYSE:PFE)’s stock price rose 1.2% during mid-day trading on Wednesday after Guggenheim raised their price target on the stock from $35.00 to $36.00. Guggenheim currently has a buy rating on the stock. Pfizer traded as high as $27.53 and last traded at $27.2860. Approximately 33,924,014 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 46,587,574 shares. The stock had previously closed at $26.96.

PFE has been the subject of a number of other reports. Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the company a “positive” rating in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.19.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 TALAPRO-3 topline results for TALZENNA® (supports late‑stage oncology positioning), which bolsters Pfizer’s mid/late‑stage pipeline and revenue optionality. Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®
• Positive Sentiment: Encouraging oncology and immunology clinical updates (positive phase 2 atirmociclib in metastatic breast cancer; topline tilrekimig eczema data) and management’s plan for ~20 pivotal trial starts this year—supports the narrative that growth is shifting beyond legacy COVID revenues. Pfizer’s Oncology And Immunology Wins Shift Focus Beyond COVID Revenues
• Positive Sentiment: Market coverage noting Pfizer outperformed the broader market decline today, citing the above pipeline momentum and analyst commentary as reasons for the relative strength. Why the Market Dipped But Pfizer (PFE) Gained Today
• Positive Sentiment: Analyst optimism: a Guggenheim analyst publicly expects PFE shares to rise, reinforcing bullish sentiment among some institutional investors. Pfizer (NYSE:PFE) Stock Price Expected to Rise, Guggenheim Analyst Says
• Neutral Sentiment: Citi maintains a Hold on Pfizer—signal that some large sell‑side desks remain cautious despite pipeline momentum. Citi Remains a Hold on Pfizer (PFE)
• Neutral Sentiment: Broader industry context: oncology is undergoing rapid innovation (immunotherapy, targeted drugs, AI) which is a tailwind for large oncology players but also raises R&D and competitive intensity. Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
• Neutral Sentiment: Non‑company AI/benefits funding news (unrelated to Pfizer fundamentals) — sector interest in AI persists but limited direct impact on PFE. AI-powered Benefits Platform Origin Raises $30 Million Series A+
• Negative Sentiment: Dividend safety concerns: several pieces highlight that Pfizer’s high yield (~6%+) raises questions about payout sustainability and could pressure the stock if cash flow or M&A dynamics change. Income investors may be re‑evaluating position sizing. Income Investors Face a Hard Truth About Pfizer’s Payout Safety
• Negative Sentiment: Competitive pressure: label expansions for rivals (e.g., BMY’s Opdivo) underscore intensifying competition in IO that could cap pricing/patient share in key oncology markets. Will the Recent Label Expansion of BMY’s Opdivo Boost Its IO Franchise?

Institutional Investors Weigh In On Pfizer

Institutional investors have recently added to or reduced their stakes in the stock. Triad Wealth Partners LLC raised its holdings in shares of Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares in the last quarter. ETF Store Inc. boosted its stake in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares in the last quarter. Mattern Wealth Management LLC grew its position in Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 400 shares during the period. Pines Wealth Management LLC grew its position in Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 400 shares during the period. Finally, Peak Asset Management LLC raised its stake in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 402 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.9%

The stock has a market capitalization of $156.59 billion, a price-to-earnings ratio of 20.25 and a beta of 0.47. The firm has a 50 day simple moving average of $26.82 and a 200-day simple moving average of $25.67. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the company earned $0.63 EPS. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.